Clincosm LogoSign in Get a demo

Holographic Mm-Wave Imaging in Patients Undergoing Radiation Therapy

Sponsor
University of Southern California (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03789773
Collaborator
National Cancer Institute (NCI) (NIH)
10
Enrollment
1
Location
1
Arm
24
Anticipated Duration (Months)
0.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This trial studies the quality of holographic mm-wave imaging in patients undergoing radiation therapy. Holographic mm-wave imaging is a common type of imaging used in airport body scanners that may be helpful in improving the efficiency and positioning of radiation oncology patients and their overall experience.

Condition or Disease Intervention/Treatment Phase
  • Device: Millimeter-Wave Holographic Imaging
 N/A

Detailed Description

PRIMARY OBJECTIVES:
  1. To obtain patient images in a clinical setting and assess their quality.
SECONDARY OBJECTIVES:
  1. To assess the registration agreement through a voxel-voxel distance-to-agreement metric.
OUTLINE:

Patients undergo holographic mm-wave imaging in radiotherapy treatment position after initial computed tomography (CT) simulation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Holographic Mm-wave Imaging in Radiation Oncology
Anticipated Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Diagnostic (holographic mm-wave imaging)

Patients undergo holographic mm-wave imaging in radiotherapy treatment position after initial CT simulation.

Device: Millimeter-Wave Holographic Imaging
Undergo mm-wave holographic imaging
Other Names:
  • Holographic Millimeter-wave Imaging; Holographic mm-Wave Imaging; MMW Holographic Imaging; Millimeter-wave Imaging; MMW Imaging; MMW

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Qualitative assessment of holographic image quality [Up to 1 year]

      Qualitative assessment of image quality by study physicians according to the scoring of each image as: 1 = High Quality (A); 2= Acceptable Quality (B); 3 = Poor/Unacceptable Quality (C). Lower value (1) represents a better score than higher value (3). There are no subscales and or total scores. The quality scores of the images will be tabulated.

    Secondary Outcome Measures

    1. Image registration agreement between mm-wave holographic images and a cone-beam computed tomography (CBCT)/optical surface image [Up to 1 year]

      The distribution of the percent of points in voxel-voxel analysis to agree to better than 2 mm will be tabulated

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Patients who are scheduled to receive either an optical or CBCT imaging scan as part of their treatment management.

    • The study will be open to English and Spanish speaking participants.

    Exclusion Criteria:
    • Patients that are not scheduled for fluoroscopic or optical imaging as part of the normal course of radiotherapy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 USC / Norris Comprehensive Cancer Center Los Angeles California United States 90033

    Sponsors and Collaborators

    • University of Southern California
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Michael Reilly, University of Southern California

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Southern California
    ClinicalTrials.gov Identifier:
    NCT03789773
    Other Study ID Numbers:
    • 0S-18-6
    • NCI-2018-02994
    • 0S-18-6
    • P30CA014089
    First Posted:
    Dec 31, 2018
    Last Update Posted:
    Aug 9, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No

    Study Results

    No Results Posted as of Aug 9, 2022